← Leaderboards

G David Roodman

University Of Texas Hlth Sci Ctr San Ant

Google Scholar ↗PubMed ↗ORCID ↗

$13,528,230

Attributed

$15,510,918

Total exposure

20

Grants

13

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.9M · FY2005–22

$2M$1.5M$1M$500K$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

Funding mix

By agency

NIH$21,894,390 · 20

VA$0 · 1

By mechanism

R01$13,579,033 · 8

P01$6,845,804 · 4

M01$741,203 · 4

R21$691,100 · 2

R13$37,250 · 2

I01$0 · 1

Top collaborators

Most similar at University Of Texas Hlth Sci Ctr San Ant

Same institution · by research overlap

Sakamuri V. Reddy$2,018,756

Others in their field

Top investigators on “Osteoclasts”

Brendan Hl Lee · Baylor College Of Medicine$18,789,257
Steven L Teitelbaum · Washington University$16,498,459
Mone Zaidi · Icahn School Of Medicine At Mount Sinai$16,089,949
Karl Leonard Insogna · Yale University$15,344,415
Yi-Ping Li · Tulane University Of Louisiana$14,733,549
Yongwon Choi · University Of Pennsylvania$14,421,139

Research focus

OsteoclastsCellsIn VivoBoneMultiple MyelomaOsteoblastsBone MarrowOsteogenesisMediatingIn VitroProductionSignal TransductionCytokineBone DiseasesReceptorStromal CellsTissue /Cell CulturePlayBaseTnfsf11 GeneInterleukin-6GenesInhibitor/AntagonistGene Expression

Grant awards (85)

Osteoclast-Osteocyte Interaction's in Paget's Disease$526,359

R01 · FY2022 · AR · contact PI

Manipulating the N-end Rule Protein Degradation Pathway to Build Bone and Decrease Tumor Growth in Multiple Myeloma Bone Disease$325,822

R01 · FY2022 · CA · contact PI

Contribution of Osteocytes to the Musculoskeletal Effects of Multiple Myeloma$409,850

R01 · FY2021 · CA

Manipulating the N-end Rule Protein Degradation Pathway to Build Bone and Decrease Tumor Growth in Multiple Myeloma Bone Disease$332,471

R01 · FY2021 · CA · contact PI

Contribution of Osteocytes to the Musculoskeletal Effects of Multiple Myeloma$349,622

R01 · FY2020 · CA

Manipulating the N-end Rule Protein Degradation Pathway to Build Bone and Decrease Tumor Growth in Multiple Myeloma Bone Disease$332,471

R01 · FY2020 · CA · contact PI

Contribution of Osteocytes to the Musculoskeletal Effects of Multiple Myeloma$75,058

R01 · FY2020 · CA

Contribution of Osteocytes to the Musculoskeletal Effects of Multiple Myeloma$411,939

R01 · FY2019 · CA · contact PI

Contribution of Osteocytes to the Musculoskeletal Effects of Multiple Myeloma$403,994

R01 · FY2018 · CA · contact PI

MVNP, p62P392L and IL-6 in the Pathogenesis of PD$380,064

R01 · FY2018 · AR · contact PI

Role of Gfi-1 in Myeloma Bone Disease$0

I01 · FY2018 · VA · contact PI

Contribution of Osteocytes to the Musculoskeletal Effects of Multiple Myeloma$402,712

R01 · FY2017 · CA · contact PI

MVNP, p62P392L and IL-6 in the Pathogenesis of PD$380,064

R01 · FY2017 · AR · contact PI

Cancer and Bone Society (CABS) Meeting 2017$2,250

R13 · FY2017 · CA · contact PI

Role of Gfi-1 in Myeloma Bone Disease$0

I01 · FY2017 · VA · contact PI

MVNP, p62P392L and IL-6 in the Pathogenesis of PD$380,305

R01 · FY2016 · AR · contact PI

Role of Gfi-1 in Myeloma Bone Disease$0

I01 · FY2016 · VA · contact PI

MVNP, p62P392L and IL-6 in the Pathogenesis of PD$393,822

R01 · FY2015 · AR · contact PI

Role of Microenvironmental-Derived AXII in Myeloma Bone Disease$0

I01 · FY2015 · VA · contact PI

MVNP, p62P392L and IL-6 in the Pathogenesis of PD$369,495

R01 · FY2014 · AR · contact PI

GFI-1 and Osteoblast Suppression in Multiple Myeloma$272,051

R01 · FY2014 · AR

Hypersensitivity of Multiple Myeloma Bone Disease to Vitamin D$197,473

R21 · FY2014 · CA · contact PI

Role of Microenvironmental-Derived AXII in Myeloma Bone Disease$0

I01 · FY2014 · VA · contact PI

GFI-1 and Osteoblast Suppression in Multiple Myeloma$263,723

R01 · FY2013 · AR

Hypersensitivity of Multiple Myeloma Bone Disease to Vitamin D$169,650

R21 · FY2013 · CA · contact PI

Role of Microenvironmental-Derived AXII in Myeloma Bone Disease$0

I01 · FY2013 · VA · contact PI

Role of Microenvironmental-Derived AXII in Myeloma Bone Disease$0

I01 · FY2013 · VA · contact PI

MVNP, p62P392L and IL-6 in the Pathogenesis of PD$349,723

R01 · FY2012 · AR · contact PI

GFI-1 and Osteoblast Suppression in Multiple Myeloma$277,603

R01 · FY2012 · AR

GFI-1 and Osteoblast Suppression in Multiple Myeloma$277,603

R01 · FY2011 · AR

MVNP, p62P392L and IL-6 in the Pathogenesis of PD$171,520

R01 · FY2011 · AR · contact PI

MVNP, p62P392L and IL-6 in the Pathogenesis of PD$144,762

R01 · FY2011 · AR · contact PI

AXII in the Multiple Myeloma Bone Microenvironment$101,332

R21 · FY2011 · CA · contact PI

AXII in the Multiple Myeloma Bone Microenvironment$71,628

R21 · FY2011 · CA · contact PI

MVNP, p62P392L and IL-6 in the Pathogenesis of PD$336,592

R01 · FY2010 · AR · contact PI

GFI-1 and Osteoblast Suppression in Multiple Myeloma$294,863

R01 · FY2010 · AR · contact PI

AXII in the Multiple Myeloma Bone Microenvironment$151,017

R21 · FY2010 · CA · contact PI

MVNP, p62P392L and IL-6 in the Pathogenesis of PD$610,272

R01 · FY2009 · AR · contact PI

MVNP, p62P392L and IL-6 in the Pathogenesis of PD$331,179

R01 · FY2009 · AR · contact PI

Osteoclasts from Transgenic Mice$256,441

R01 · FY2009 · AR · contact PI

MVNP, p62P392L and IL-6 in the Pathogenesis of PD$345,005

R01 · FY2008 · AR · contact PI

Osteoclasts from Transgenic Mice$256,458

R01 · FY2008 · AR · contact PI

Program Project Grant-Pathobiology of Paget's Disease$778,991

P01 · FY2007 · AR · contact PI

Osteoclasts from Transgenic Mice$261,708

R01 · FY2007 · AR · contact PI

Development of In Vivo Models of Paget's Disease$200,071

P01 · FY2007 · AR · contact PI

Administrative Core$80,747

P01 · FY2007 · AR · contact PI

Program Project Grant-Pathobiology of Paget's Disease$1,234,768

P01 · FY2006 · AR · contact PI

Osteoclasts from Transgenic Mice$269,540

R01 · FY2006 · AR · contact PI

Paget's Disease of Bone/Dysplasia:Advances/Challenges$20,000

R13 · FY2006 · AR · contact PI

Program Project Grant-Pathobiology of Paget's Disease$1,328,629

P01 · FY2005 · AR

Osteoclasts from Transgenic Mice$286,713

R01 · FY2005 · AR

Developmental Aspects of Osteoclast Formation In Vitro$258,550

R01 · FY2005 · AG

Paget's Disease of Bone/Dysplasia:Advances/Challenges$15,000

R13 · FY2005 · AR

DEVELOPMENTAL ASPECTS OF OSTEOCLAST FORMATION IN VITRO$3,664

M01 · FY2005 · RR

PATHOBIOLOGY OF THE OSTEOCLAST IN PAGET'S DISEASE$3,664

M01 · FY2005 · RR

PH I TRL OF BORTEZOMIB &FLAVOPIRIDOL PTS B-CELL$999

M01 · FY2005 · RR

Program Project Grant-Pathobiology of Paget's Disease$1,291,048

P01 · FY2004 · AR

Developmental Aspects of Osteoclast Formation In Vitro$258,805

R01 · FY2004 · AG

Developmental Aspects of Osteoclast Formation in Vitro$11,447

M01 · FY2004 · RR

Pathobiology of the Osteoclast in Paget's Disease$509

M01 · FY2004 · RR

Program Project Grant-Pathobiology of Paget's Disease$1,750,036

P01 · FY2003 · AR

Developmental Aspects of Osteoclast Formation In Vitro$259,057

R01 · FY2003 · AG

OSTEOCLASTS FROM TRANSGENIC MICE$248,869

R01 · FY2003 · AR

PATHOBIOLOGY OF THE OSTEOCLAST IN PAGETS DISEASE$325,788

R01 · FY2002 · AR

Developmental Aspects of Osteoclast Formation In Vitro$260,604

R01 · FY2002 · AG

OSTEOCLASTS FROM TRANSGENIC MICE$242,627

R01 · FY2002 · AR

LONGITUDINAL EVALUATION OF CHANGES IN CYTOKINES IN MULTIPLE MYELOMA$234,837

M01 · FY2002 · RR

LONGITUDINAL EVALUATION OF CHANGES IN CYTOKINES IN MULTIPLE MYELOMA$234,837

M01 · FY2002 · RR

Myeloma and osteolytic bone lesions$0

P01 · FY2002 · CA

Myeloma and osteolytic bone lesions$0

P01 · FY2002 · CA

Myeloma and osteolytic bone lesions$0

P01 · FY2002 · CA

Myeloma and osteolytic bone lesions$0

P01 · FY2002 · CA

Developmental Aspects of Osteoclast Formation In Vitro$240,398

R01 · FY2001 · AG

OSTEOCLASTS FROM TRANSGENIC MICE$236,562

R01 · FY2001 · AR

PATHOBIOLOGY OF THE OSTEOCLAST IN PAGETS DISEASE$236,299

R01 · FY2001 · AR

LONGITUDINAL EVALUATION OF CHANGES IN CYTOKINES IN MULTIPLE MYELOMA$234,837

M01 · FY2001 · RR

Developmental Aspects of Osteoclast Formation In Vitro$12,477

R01 · FY2001 · AG

Myeloma and osteolytic bone lesions$0

P01 · FY2001 · CA

Myeloma and osteolytic bone lesions$0

P01 · FY2001 · CA

OSTEOCLASTS FROM TRANSGENIC MICE$230,676

R01 · FY2000 · AR

Myeloma and osteolytic bone lesions$181,514

P01 · FY2000 · CA

PATHOBIOLOGY OF THE OSTEOCLAST IN PAGETS DISEASE$128,082

R01 · FY2000 · AR

PATHOBIOLOGY OF THE OSTEOCLAST IN PAGETS DISEASE$102,000

R01 · FY2000 · AR

DEVELOPMENTAL ASPECTS OF OSTEOCLAST FORMATION IN VITRO$58,435

R01 · FY2000 · AG

LONGITUDINAL EVALUATION OF CHANGES IN CYTOKINES IN MULTIPLE MYELOMA$16,409

M01 · FY2000 · RR